Works matching AU Nitsche, Marcus

Results: 3

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Published in:
Blood Cancer Journal, 2022, v. 12, n. 4, p. 1, doi. 10.1038/s41408-022-00660-2
By:
- Albinger, Nawid;
- Pfeifer, Rita;
- Nitsche, Marcus;
- Mertlitz, Sarah;
- Campe, Julia;
- Stein, Katja;
- Kreyenberg, Hermann;
- Schubert, Ralf;
- Quadflieg, Melissa;
- Schneider, Dina;
- Kühn, Michael W. M.;
- Penack, Olaf;
- Zhang, Congcong;
- Möker, Nina;
- Ullrich, Evelyn
Publication type:
Article
CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
Published in:
Frontiers in Immunology, 2022, v. 12, p. 1, doi. 10.3389/fimmu.2021.798087
By:
- Hejazi, Maryam;
- Congcong Zhang;
- Bennstein, Sabrina B.;
- Baiz, Vera;
- Reusing, Sarah B.;
- Quadflieg, Melissa;
- Hoerster, Keven;
- Heinrichs, Stefan;
- Hanenberg, Helmut;
- Oberbeck, Sebastian;
- Nitsche, Marcus;
- Cramer, Sophie;
- Pfeifer, Rita;
- Oberoi, Pranav;
- Rühi, Heiko;
- Oldenburg, Johannes;
- Brossart, Peter;
- Horn, Peter A.;
- Babor, Florian;
- Wels, Winfried S.
Publication type:
Article
Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia.
Published in:
Hematological Oncology, 2023, v. 41, n. 3, p. 520, doi. 10.1002/hon.3100
By:
- Wilhelm, Thomas;
- Toledo, Marcelo A. S.;
- Simons, Ilka;
- Stuth, Christian;
- Mohta, Vrinda;
- Mülfarth, Ronja;
- Nitsche, Marcus;
- Maschke‐Neuß, Karin;
- Schmitz, Susanne;
- Kaiser, Anne;
- Panse, Jens;
- Christen, Deborah;
- Arock, Michel;
- Zenke, Martin;
- Huber, Michael
Publication type:
Article

Works matching AU Nitsche, Marcus

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.

Capitalizing on paradoxical activation of the mitogen‐activated protein kinase pathway for treatment of Imatinib‐resistant mast cell leukemia.